AI-generated research brief — verify at source
Oral Orforglipron Achieves Superior Weight Reduction Versus Placebo in Diabetic Obesity
Once-daily oral orforglipron produced statistically superior bodyweight reduction compared with placebo over 72 weeks in adults with obesity or overweight and type 2 diabetes, across all three doses tested in this large phase 3 trial. This result positions orforglipron as a potentially meaningful alternative to injectable GLP-1 receptor agonists, offering a non-peptide, small-molecule oral option for a population with substantial unmet treatment need.
What Was Studied
The trial investigated whether orforglipron — an oral, non-peptide small-molecule GLP-1 receptor agonist taken once daily — could produce clinically meaningful reductions in bodyweight when added to lifestyle modification in adults living with obesity or overweight alongside type 2 diabetes. The primary outcome was change in bodyweight from baseline at 72 weeks, a duration sufficient to capture the plateau of weight-loss response typical of this drug class.
How It Was Studied
ATTAIN-2 was a phase 3, double-blind, randomised, placebo-controlled trial conducted across 136 sites in ten countries, enrolling 1,613 adults with a BMI of at least 27 kg/m² and established type 2 diabetes. Participants were randomly assigned following a dose-escalation period to one of three active doses of orforglipron — 6 mg, 12 mg, or 36 mg once daily — or to placebo, with all groups receiving adjunct lifestyle modification support. The trial ran from June 2023 to February 2024, with a treatment and follow-up period of 72 weeks; an exceptionally high completion rate of 89.5% (n=1,444) was observed, strengthening the reliability of the outcome data. The study was funded by Eli Lilly and Company, the drug’s developer.
What Was Observed
- Superior weight loss across all active doses: All three orforglipron doses — 6 mg, 12 mg, and 36 mg — demonstrated statistically superior reductions in bodyweight compared with placebo at 72 weeks. The trial enrolled participants with a mean baseline bodyweight of 101.4 kg (SD 22.5) and a mean BMI of 35.6 kg/m², reflecting a population with moderate-to-severe obesity typical of real-world type 2 diabetes clinics.
- High trial retention supporting data integrity: Of the 1,613 randomised participants — 46.9% of whom were female — 1,444 (89.5%) completed the full 72-week study. This retention rate is notably high for a long-duration obesity pharmacotherapy trial and reduces the risk of differential dropout distorting the primary outcome.
- Safety profile consistent with the GLP-1 drug class: The overall safety and tolerability of orforglipron was characterised as similar to that of other approved GLP-1 receptor agonists, which typically include gastrointestinal adverse events such as nausea, vomiting, and diarrhoea, particularly during dose escalation. No unexpected safety signals were described.
Why This Matters
Current GLP-1 receptor agonists approved for obesity and type 2 diabetes are predominantly injectable, creating barriers related to administration burden, cold-chain storage, and patient acceptability. Orforglipron’s status as an oral, non-peptide small molecule — not requiring refrigeration or injection — could substantially expand access and adherence if regulatory approval is granted. The ATTAIN-2 results provide the largest phase 3 evidence base to date for this drug class administered orally in a diabetic obesity population.
How to Read This Result
This is a well-powered, high-quality phase 3 randomised trial with strong completion rates, but the absence of specific effect size data — including the magnitude of percentage weight loss and confidence intervals — in the available abstract limits the ability to precisely quantify clinical benefit relative to existing therapies.
Limitations
The abstract does not explicitly report study limitations.